November 2, 2017 10:28 AM EDT

Focusing on next-gen cancer drugs, GSK touts a ‘breakthrough’ at FDA; Aisling raises $280M fund

John Carroll

Editor & Founder

→ Anyone looking for fresh signs of GlaxoSmithKline’s plans to go much deeper into oncology should check out the pharma giant’s notice that its multiple …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Focusing on next-gen cancer drugs, GSK touts a ‘breakthrough’ at FDA; Aisling raises $280M fund

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Fo­cus­ing on next-gen can­cer drugs, GSK touts a ‘break­through’ at FDA; Ais­ling rais­es $280M fund

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Focusing on next-gen cancer drugs, GSK touts a ‘breakthrough’ at FDA; Aisling raises $280M fund

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.